Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

European Journal of Pharmacology
Atsuo TaharaEiji Kurosaki

Abstract

In this study, we investigated and compared the effects of all six sodium-glucose cotransporter (SGLT) 2 inhibitors commercially available in Japan on diabetes-related diseases and complications in type 2 diabetic mice. Following 4-week repeated administration to diabetic mice, all SGLT2 inhibitors showed significant improvement in diabetes-related diseases and complications, including obesity; abnormal lipid metabolism; steatohepatitis; inflammation; endothelial dysfunction; and nephropathy. While all SGLT2 inhibitors exerted comparable effects in reducing hyperglycemia, improvement of these diabetes-related diseases and complications was more potent with the two long-acting drugs (ipragliflozin and dapagliflozin) than with the four intermediate-acting four drugs (tofogliflozin, canagliflozin, empagliflozin, and luseogliflozin), albeit without statistical significance. These findings demonstrate that SGLT2 inhibitors alleviate various diabetic pathological conditions in type 2 diabetic mice, and suggest that SGLT2 inhibitors, particularly long-acting drugs, might be useful not only for hyperglycemia but also in diabetes-related diseases and complications, including nephropathy in type 2 diabetes.

Citations

Jan 22, 2019·Current Medicinal Chemistry·Anastasios TentolourisNikolaos Tentolouris
Feb 9, 2019·Cardiovascular Diabetology·Damilola D AdingupuAnn-Cathrine Jönsson-Rylander
Jan 25, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Mitsuhiro KondoYuichi Tomura
Jul 28, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Afnan S AlshnbariIskandar Idris
Jul 13, 2019·International Journal of Molecular Sciences·Keiichiro MatobaRimei Nishimura
Nov 24, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yupeng JiangLijian Tao
May 16, 2020·Drug Discovery Today·Frederikke E SembachLisbeth N Fink
Jan 15, 2021·International Journal of Molecular Sciences·María Aguilar-BallesterHerminia González-Navarro
Jun 17, 2021·Nature Reviews. Endocrinology·Daniel Ferguson, Brian N Finck
Dec 23, 2019·Cardiology·Diogo Santos-FerreiraRicardo Fontes-Carvalho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here